DanDrit Biotech USA, a United States-based clinical-stage company, has completed the acquisition of Enochian Biopharma, a gene therapy company.

It was reported yesterday that As a result of the deal, DanDrit owns a perpetual, fully paid up, royalty free, sub-licensable, exclusive, license to new technology platforms intended for the treatment of HIV, including combinatory gene therapy methods, and Enochian is now a wholly owned subsidiary of DanDrit.

Due to the deal, Enochian stockholders received 18,081,962 shares of DanDrit's common stock, representing 50% of DanDrit's common stock issued and outstanding, after giving effect to the private placements, the warrant exercises and the acquisition, and expenses related to the acquisition. The Enochian stockholders will also have the right receive pro rata shares of DanDrit's common stock upon the exercise or conversion of any of DanDrit's warrants currently outstanding.